# AstraZeneca Secures FDA Approval For Baxfendy In Hypertension.

*biotech · news · 2026-05-18 · Benzinga*

## Key points

- AstraZeneca won FDA approval for Baxfendy, a new aldosterone-blocking hypertension drug for resistant cases.
- Baxfendy's approval was based on Phase 3 BaxHTN trial data showing significant blood pressure reduction.
- FDA expanded Enhertu approvals to both neoadjuvant and adjuvant settings for HER2-positive early breast cancer.
- In DESTINY-Breast05, Enhertu halved the risk of disease recurrence or death compared to trastuzumab emtansine.
- AstraZeneca owes Daiichi Sankyo $155 million in milestone payments following the Enhertu approvals.

**Companies:** AstraZeneca, Daiichi Sankyo
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/fda/26/05/52642817/astrazeneca-scores-key-fda-wins-across-cardiovascular-and-oncology-portfolios)

---

Canonical: https://newsio.io/n/6eee8a24-f07a-4299-90d0-ea37bb66563b/astrazeneca-secures-fda-approval-for-baxfendy-in-hypertension-company-also-annou
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works